德国、奥地利和瑞士39家皮肤癌中心使用PD-1抗体与BRAF+MEK抑制剂辅助治疗黑色素瘤的真实世界结局
这项多中心回顾性研究分析了德国、奥地利和瑞士39家皮肤癌中心2017年1月至2021年10月间接受辅助尼伏鲁单抗、帕博利珠单抗或达拉非尼+曲美替尼治疗的1198例III-IV期黑色素瘤患者。抗PD-1治疗与BRAF+MEK抑制剂治疗的12个月无复发生存率分别为78.1%和86.5%(HR 1.998,95%CI 1.335-2.991,p=0.001),总生存无显著差异。发生免疫相关不良事件的患者复发率较低(HR 0.578,95%CI 0.443-0.754,p=0.001)。
要点
- 抗PD-1治疗12个月无复发生存率为78.1%,BRAF+MEK抑制剂为86.5%,HR 1.998(95%CI 1.335-2.991,p=0.001)。
- 抗PD-1治疗中发生免疫相关不良事件者复发率较低(HR 0.578,95%CI 0.443-0.754,p=0.001)。
- 总淋巴结清扫与仅前哨淋巴结活检相比,12个月无复发生存和总生存均无显著差异(p>0.05)。
核心结论
- 尽管辅助黑色素瘤治疗取得进展,早期复发仍是重要临床挑战。
- 总淋巴结清扫不降低早期黑色素瘤复发风险,作者认为应仅考虑用于特定患者。
- 临床常规收集的变量不太可能实现对个体复发风险的临床相关预测。
研究设计与样本
- 多中心回顾性研究,纳入德国、奥地利和瑞士39家皮肤癌中心2017年1月至2021年10月间接受辅助尼伏鲁单抗、帕博利珠单抗或达拉非尼+曲美替尼治疗的III-IV期黑色素瘤患者,共1198例。
主要发现
- 抗PD-1治疗组(n=1003)与BRAF+MEK抑制剂组12个月无复发生存率分别为78.1%和86.5%(HR 1.998,95%CI 1.335-2.991,p=0.001)。
- 中位随访17个月期间,抗PD-1治疗组总生存率95.8%与BRAF+MEK抑制剂组96.9%无统计学显著差异(p>0.05)。
- 抗PD-1治疗患者中,发生免疫相关不良事件者较未发生者复发率更低(HR 0.578,95%CI 0.443-0.754,p=0.001)。
- BRAF突变状态不影响抗PD-1治疗总体疗效(p>0.05)。
- 在抗PD-1和BRAF+MEK抑制剂两组中,总淋巴结清扫与仅前哨淋巴结活检相比,12个月无复发生存和12个月总生存均无显著差异(p>0.05)。
关键数值与推荐
- 复发预测模型达到高特异性但仅低灵敏度,AUC=0.65。
- 未检测到新的安全性信号,记录的不良事件数量和严重程度低于关键III期试验报告。
临床怎么用
- 作者认为总淋巴结清扫不降低早期黑色素瘤复发风险,应仅考虑用于特定患者。
- 数据表明临床常规收集的变量不太可能实现对个体复发风险的临床相关预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed death-1 (PD-1) antibodies and BRAF + MEK inhibitors are widely used for adjuvant therapy of fully resected high-risk melanoma. Little is known about treatment efficacy outside of phase III trials. This real-world study reports on clinical outcomes of modern adjuvant melanoma treatment in specialized skin cancer centers in Germany, Austria and Switzerland. METHODS: Multicenter, retrospective study investigating stage III-IV melanoma patients receiving adjuvant nivolumab (NIV), pembrolizumab (PEM) or dabrafenib + trametinib (D + T) between 1/2017 and 10/2021. The primary endpoint was 12-month recurrence-free survival (RFS). Further analyses included descriptive and correlative statistics, and a multivariate linear-regression machine learning model to assess the risk of early melanoma recurrence. RESULTS: In total, 1198 patients from 39 skin cancer centers from Germany, Austria and Switzerland were analysed. The vast majority received anti PD-1 therapies (n = 1003). Twelve-month RFS for anti PD-1 and BRAF + MEK inhibitor-treated patients were 78.1% and 86.5%, respectively (hazard ratio [HR] 1.998 [95% CI 1.335-2.991]; p = 0.001). There was no statistically significant difference in overall survival (OS) in anti PD-1 (95.8%) and BRAF + MEK inhibitor (96.9%) treated patients (p > 0.05) during the median follow-up of 17 months. Data indicates that anti PD-1 treated patients who develop immune-related adverse events (irAEs) have lower recurrence rates compared to patients with no irAEs (HR 0.578 [95% CI 0.443-0.754], p = 0.001). BRAF mutation status did not affect overall efficacy of anti PD-1 treatment (p > 0.05). In both, anti PD-1 and BRAF + MEK inhibitor treated cohorts, data did not show any difference in 12-month RFS and 12-month OS comparing patients receiving total lymph node dissection (TLND) versus sentinel lymph node biopsy only (p > 0.05). The recurrence prediction model reached high specificity but only low sensitivity with an AUC = 0.65. No new safety signals were detected. Overall, recorded numbers and severity of adverse events were lower than reported in pivotal phase III trials. CONCLUSIONS: Despite recent advances in adjuvant melanoma treatment, early recurrence remains a significant clinical challenge. This study shows that TLND does not reduce the risk of early melanoma recurrence and should only be considered in selected patients. Data further highlight that variables collected during clinical routine are unlikely to allow for a clinically relevant prediction of individual recurrence risk.
引用
- Schumann K, Mauch C, Klespe KC, et al. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. J Eur Acad Dermatol Venereol. 2022. PMID: 36433688. doi:10.1111/jdv.18779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。